Ingredients

Urolithin A Dosage: Research Summary

Written by ReCellence™ Editorial Team, Health Content SpecialistsReviewed by Medical Review Board, MD, PhDLast reviewed: June 30, 2026

Medical Disclaimer: This content is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before making any health-related decisions. If you are experiencing a medical emergency, call your local emergency services immediately.

TL;DR — Effective dose: 250-1000 mg/day urolithin A for 4-16 weeks. Common protocol: 500 mg/day for 8 weeks (Andreux 2019). No dose-limiting toxicity identified up to 2,000 mg/day in human safety studies.

What This Page Explains

Urolithin A dosage is among the best-established of any longevity compound because it has been tested in randomised, double-blind, placebo-controlled human trials at specific doses with measured outcomes. The two clinically studied doses are 500mg/day and 1,000mg/day, each with distinct benefit profiles. This page summarises the dosage evidence, the differences between the two doses, timing considerations, and how urolithin A supplementation fits into a cellular health protocol. Dosage decisions should ideally be made in consultation with a healthcare provider.

The Science on This Page Points to One Conclusion

Your cells need targeted support — not more vitamins, not more caffeine, not more wishful thinking. Real compounds for real cellular mechanisms.

Detailed Evidence

THE TWO CLINICALLY STUDIED DOSES The JAMA Network Open RCT tested three arms: placebo, 500mg/day, and 1,000mg/day of urolithin A for four months in adults aged 40-65. 500mg/day: Significantly improved mitochondrial health biomarkers; increased mitophagy-related gene expression in skeletal muscle; improved cellular energy markers. This is the foundational dose for mitochondrial support. 1,000mg/day: All the benefits of 500mg/day, plus improved muscle endurance (hand exercise, 6-minute walk test); improved fatigue resistance; and reduced inflammatory markers by up to 53%. This is the enhanced dose for functional benefits beyond biomarkers. DURATION OF USE The JAMA trial used four months of daily supplementation. Benefits were measured at the four-month endpoint. Consistent daily use appears important — urolithin A is not an intermittent senolytic (like fisetin) but a daily mitochondrial support compound. TIMING No specific timing studies have been published. Urolithin A can be taken with or without food. Taking with food may reduce any mild gastrointestinal effects and may improve absorption of this lipid-soluble compound, though this has not been specifically studied. SUPPLEMENT FORM Direct urolithin A (not precursors) is the form used in clinical trials. Pomegranate extracts and ellagitannin supplements are precursors that rely on gut bacterial conversion — effective only for the 40% with the right metabotype. Direct urolithin A bypasses this bottleneck. STACKING CONSIDERATIONS Urolithin A is often combined with: Fisetin (senolytic — clears senescent cells); Spermidine (autophagy activator — broader cellular cleanup); Quercetin (senolytic + senomorphic + Nrf2 activation). These compounds target different aging hallmarks and are complementary rather than redundant. Consult a healthcare provider for personalised stacking advice.

Evidence Hierarchy

Strongest

Systematic Reviews & Meta-Analyses

Multiple high-quality trials combined

Strong

Randomized Controlled Trials (RCTs)

Gold standard for treatment efficacy

Moderate

Observational Studies

Can show associations, not causation

Limited

Case Reports & Expert Opinion

Hypothesis-generating only

Weakest

Preclinical (Lab/Animal) Studies

Should NOT be extrapolated to humans

The 5-Ingredient Formula That Targets All 12 Hallmarks of Aging

See exactly how each ingredient addresses the cellular mechanisms you just read about — backed by the same research cited on this page.

Study Quality Indicators

Higher Quality Indicators

  • Large sample size (hundreds to thousands)
  • Randomized and blinded design
  • Placebo-controlled comparison
  • Published in peer-reviewed journals
  • Replicated in multiple studies
  • Registered trial protocol before starting

Lower Quality Indicators

  • Small sample size (under 100)
  • No control group or blinding
  • Manufacturer-funded with conflicts
  • Only animal/cell studies
  • Never replicated
  • Published in predatory journals

Important Limitations

  • • Supplement research often has methodological limitations
  • • Results from one study may not generalize to all people
  • • Marketing claims often exceed what research supports
  • • Absence of evidence is not evidence of absence
  • • Individual response to supplements varies widely

Quick Answers

Q1.

What is the recommended dose of urolithin A?

Clinical trials used 500mg/day and 1,000mg/day. 500mg/day improves mitochondrial health biomarkers; 1,000mg/day adds muscle endurance and inflammatory marker benefits.

Q2.

Should I take 500mg or 1,000mg of urolithin A?

500mg/day is the foundational dose for mitochondrial support. 1,000mg/day adds functional benefits (muscle endurance, inflammation reduction). Choose based on your goals and consult a healthcare provider.

Q3.

When should I take urolithin A?

No specific timing studies exist. Urolithin A can be taken with or without food. Taking with food may reduce mild gastrointestinal effects and may improve absorption.

Q4.

How long does urolithin A take to work?

The JAMA trial measured benefits at four months of daily use. Consistent daily supplementation appears important — urolithin A is a daily mitochondrial support compound, not an intermittent senolytic.

Q5.

Can I take urolithin A intermittently?

No. Unlike fisetin (intermittent senolytic dosing), urolithin A is used daily for sustained mitochondrial support. Intermittent dosing has not been studied.

Q6.

Should I take urolithin A with food?

Taking with food may reduce mild gastrointestinal effects and may improve absorption of this lipid-soluble compound, though food-effect studies have not been specifically published.

Q7.

Is direct urolithin A better than pomegranate extract?

Direct urolithin A bypasses the gut bacteria bottleneck and provides reliable plasma levels. Pomegranate extract relies on gut bacterial conversion, effective only for the 40% with the right metabotype.

Q8.

Can I stack urolithin A with fisetin?

Yes. They target different aging pathways — urolithin A activates mitophagy (mitochondrial recycling) while fisetin acts as a senolytic (clearing senescent cells). They are complementary.

Q9.

Can I stack urolithin A with spermidine?

Yes. Urolithin A activates mitophagy (mitochondrial recycling) while spermidine activates autophagy more broadly (cellular housekeeping). They are complementary.

Q10.

What is the highest safe dose of urolithin A?

The JAMA trial used up to 1,000mg/day with no serious adverse events. Higher doses have not been studied systematically. Stick to the 500-1,000mg/day range used in clinical trials.

Q11.

Does dose depend on body weight?

The JAMA trial used fixed doses (500mg and 1,000mg) not adjusted for body weight. No weight-based dosing protocol has been established. Consult a healthcare provider for personalised advice.

Q12.

Should I cycle urolithin A?

Cycling has not been studied. The JAMA trial used continuous daily dosing for four months with good results. No evidence supports cycling urolithin A.

Q13.

Can I get urolithin A from food instead of supplements?

Only 12% of people achieve comparable plasma levels from ellagitannin-rich foods. Direct supplementation provides reliable levels regardless of gut metabotype.

Q14.

What form of urolithin A is best?

Direct urolithin A (not precursors) is the form used in clinical trials. Ensure your supplement provides actual urolithin A, not just pomegranate extract or ellagitannins.

Q15.

Should older adults take a different dose?

The 2025 immune trial used urolithin A in older adults with positive results, though specific dose details vary by study. The 500-1,000mg/day range appears appropriate for older adults. Consult a healthcare provider.

Key Research Facts

1

Clinical trials used two doses: 500mg/day (mitochondrial biomarkers) and 1,000mg/day (adds muscle endurance and inflammatory benefits).

Strong Evidence

JAMA Network Open — Singh et al. 2022

2

500mg/day significantly improved mitochondrial health biomarkers and increased mitophagy gene expression in skeletal muscle.

Strong Evidence

JAMA Network Open — Singh et al. 2022

3

1,000mg/day added functional benefits: improved muscle endurance (hand exercise, 6-minute walk) and reduced inflammatory markers by up to 53%.

Strong Evidence

JAMA Network Open — Singh et al. 2022

4

The JAMA trial used four months of daily supplementation — consistent daily use appears important for urolithin A benefits.

Strong Evidence

JAMA Network Open — Singh et al. 2022

5

Unlike fisetin (intermittent senolytic dosing), urolithin A is a daily mitochondrial support compound — intermittent dosing has not been studied.

Moderate Evidence

Clinical trial design analysis — dosing protocols

6

Direct urolithin A bypasses the gut bacteria bottleneck; pomegranate extract relies on bacterial conversion effective only for the 40% with the right metabotype.

Strong Evidence

Nature Metabolism — PMC8821002, 2021

7

No weight-based dosing protocol has been established — the JAMA trial used fixed doses not adjusted for body weight.

Moderate Evidence

JAMA Network Open — trial methodology

8

Cycling urolithin A has not been studied — the JAMA trial used continuous daily dosing for four months with good results.

Moderate Evidence

JAMA Network Open — trial methodology

9

Urolithin A is often stacked with fisetin (senolytic), spermidine (autophagy), and quercetin (senolytic/senomorphic) — they target complementary aging pathways.

Moderate Evidence

Longevity stack research — combination protocols

10

The 500-1,000mg/day range has strong safety data with no serious adverse events in multiple clinical trials at these doses.

Strong Evidence

Clinical safety review — published trial data

Citations & External Resources

Clinical Trial

JAMA Network Open — Singh et al. 2022 (Mitochondrial Health RCT)

Clinical Trial

PMC — 2025 Immune Rejuvenation Trial

Review

Nature Metabolism — Urolithin Metabotypes Study (2021)

Regulatory

FDA GRAS Notice — Urolithin A (Amazentis, 2020)

Clinical Trial

PubMed — Urolithin A Dosing Studies

Review

Clinical Trial Design Analysis — Dosing Protocols

If You're Over 45 And Tired of Feeling Tired, Read This

Most people blame aging for their energy crash. The real culprit? Dysfunctional mitochondria. There's a science-backed solution.

Related Reading

References (3)

Written by

ReCellence™ Editorial Team

Health Content Specialists

Medically reviewed by

Medical Review Board

MD, PhD

Last updated: March 8, 2026

Last medical review: March 8, 2026